106 related articles for article (PubMed ID: 26562405)
1. [The INCA trial (impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites): precision medicine for patients with liver cirrhosis and ascites].
Casper M; Appenrodt B; Grünhage F; Lammert F
Z Gastroenterol; 2015 Nov; 53(11):1350-2. PubMed ID: 26562405
[No Abstract] [Full Text] [Related]
2. The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial.
Casper M; Mengel M; Fuhrmann C; Herrmann E; Appenrodt B; Schiedermaier P; Reichert M; Bruns T; Engelmann C; Grünhage F; Lammert F;
Trials; 2015 Mar; 16():83. PubMed ID: 25887140
[TBL] [Abstract][Full Text] [Related]
3. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis.
Bruns T; Peter J; Reuken PA; Grabe DH; Schuldes SR; Brenmoehl J; Schölmerich J; Wiest R; Stallmach A
Liver Int; 2012 Feb; 32(2):223-30. PubMed ID: 21745302
[TBL] [Abstract][Full Text] [Related]
4. Subclinical ascites defines an intermediate stage between compensated and decompensated cirrhosis.
Zipprich A; Seufferlein T; Dollinger MM
Z Gastroenterol; 2012 Sep; 50(9):996-1001. PubMed ID: 22965629
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis.
Nischalke HD; Berger C; Aldenhoff K; Thyssen L; Gentemann M; Grünhage F; Lammert F; Nattermann J; Sauerbruch T; Spengler U; Appenrodt B
J Hepatol; 2011 Nov; 55(5):1010-6. PubMed ID: 21356257
[TBL] [Abstract][Full Text] [Related]
6. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis.
Appenrodt B; Grünhage F; Gentemann MG; Thyssen L; Sauerbruch T; Lammert F
Hepatology; 2010 Apr; 51(4):1327-33. PubMed ID: 20087966
[TBL] [Abstract][Full Text] [Related]
7. Common NOD2 Risk Variants as Major Susceptibility Factors for Bacterial Infections in Compensated Cirrhosis.
Reichert MC; Ripoll C; Casper M; Greinert R; Vandieken E; Grünhage F; Appenrodt B; Zipprich A; Lammert F
Clin Transl Gastroenterol; 2019 Jan; 10(1):e00002. PubMed ID: 30702490
[TBL] [Abstract][Full Text] [Related]
8. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
Fernández J; Ruiz del Arbol L; Gómez C; Durandez R; Serradilla R; Guarner C; Planas R; Arroyo V; Navasa M
Gastroenterology; 2006 Oct; 131(4):1049-56; quiz 1285. PubMed ID: 17030175
[TBL] [Abstract][Full Text] [Related]
9. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.
Sersté T; Melot C; Francoz C; Durand F; Rautou PE; Valla D; Moreau R; Lebrec D
Hepatology; 2010 Sep; 52(3):1017-22. PubMed ID: 20583214
[TBL] [Abstract][Full Text] [Related]
10. Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites.
Dam G; Vilstrup H; Andersen PK; Bossen L; Watson H; Jepsen P
Liver Int; 2019 Mar; 39(3):514-521. PubMed ID: 30472808
[TBL] [Abstract][Full Text] [Related]
11. NOD2 gene variants and spontaneous bacterial peritonitis.
Filik L
Liver Int; 2012 Mar; 32(3):521; author reply 521-2. PubMed ID: 22098721
[No Abstract] [Full Text] [Related]
12. [Increased survival following antibiotic prophylaxis in patients with cirrhosis and upper gastrointestinal hemorrhage].
Bendtsen F
Ugeskr Laeger; 2005 Feb; 167(7):733. PubMed ID: 15779253
[No Abstract] [Full Text] [Related]
13. [Antibiotic prophylaxis for patients with liver cirrhosis and upper gastrointestinal hemorrhage. Is there evidence for its use?].
Kofoed K; Kronborg G
Ugeskr Laeger; 2005 Feb; 167(7):735-9. PubMed ID: 15779254
[No Abstract] [Full Text] [Related]
14. EVALUATION OF PROGNOSTIC FACTORS IN DECOMPENSATED LIVER CIRRHOSIS WITH ASCITES AND SPONTANEOUS BACTERIAL PERITONITIS.
Dănulescu RM; Stanciu C; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2015; 119(4):1018-24. PubMed ID: 26793843
[TBL] [Abstract][Full Text] [Related]
15. Treatment with colchicine and survival of patients with ascitic cirrhosis: a double-blind randomized trial.
Adhami JE; Basho J
Panminerva Med; 1998 Mar; 40(1):75-81. PubMed ID: 9573762
[TBL] [Abstract][Full Text] [Related]
16. Is this really the end of beta-blockers in patients with cirrhosis and refractory ascites?
Thevenot T; Cervoni JP; Monnet E; Sheppard F; Martino VD
Hepatology; 2011 Feb; 53(2):715-6. PubMed ID: 20814893
[No Abstract] [Full Text] [Related]
17. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.
Kurt M
Hepatology; 2011 Apr; 53(4):1411-2. PubMed ID: 21225642
[No Abstract] [Full Text] [Related]
18. [Liver cirrhosis and bacterial infections].
Vilstrup H
Ugeskr Laeger; 2005 Feb; 167(7):739-41. PubMed ID: 15779255
[No Abstract] [Full Text] [Related]
19. A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis.
Das A
Am J Gastroenterol; 1998 Oct; 93(10):1895-900. PubMed ID: 9772051
[TBL] [Abstract][Full Text] [Related]
20. [Antibiotic prophylaxis after gastrointestinal hemorrhage in liver cirrhosis--for which patients, with what antibiotics?].
Gerbes AL
Z Gastroenterol; 1997 Aug; 35(8):659-60. PubMed ID: 9381749
[No Abstract] [Full Text] [Related]
[Next] [New Search]
